絞り込み

16547

広告

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.

著者 Ruperto N , Brunner HI , Quartier P , Constantin T , Wulffraat NM , Horneff G , Kasapcopur O , Schneider R , Anton J , Barash J , Berner R , Corona F , Cuttica R , Fouillet-Desjonqueres M , Fischbach M , Foster HE , Foell D , Radominski SC , Ramanan AV ,
Ann Rheum Dis.2018 Sep 29 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9view , 0users)

Full Text Sources

To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).
PMID: 30269054 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード